Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P970003/S254

VNS Therapy System

LivaNova USA, Inc. · Decision date Oct 2, 2026

MEDTECHLEDGER EXPLANATIONP970003/S254

What did the FDA approve?

FDA supplement P970003/S254 records an approval for a change in the battery voltage offset used in the battery longevity calculation for the VNS Therapy System. The offset is to be applied over 15% of battery usage instead of the previous 7.5%.

The supplement is classified as a Real-Time Process for a change in design, components, specifications, or material. The applicant is LivaNova USA, Inc., and the device category is an implanted autonomic nerve stimulator for epilepsy. The decision statement does not describe clinical testing, safety outcomes, or effectiveness data.

FDA approval order statement

approval for change in the battery voltage offset in battery longevity calculation to be applied over 15% of battery usage instead of 7.5%.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Neurology
Decision date
Oct 2, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P970003/S254
Regulatory pathway
PMA supplement
Product code
LYJ
Decision code
APPR
Decision date
Oct 2, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, autonomic nerve, implanted for epilepsy.

Product code
LYJ
FDA device class
3

For the original device and its historical approval scope, see PMA P970003. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P970003 · Original PMA

    VNS THERAPY SYSTEM

  2. P970003/S254 received

    Application receipt date recorded by FDA.

  3. P970003/S254 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P970003. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P970003

Product / regulatory recordCompanyPathwayDecision dateSource
LivaNova USA, Inc.PMA approvalJul 16, 1997FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

LivaNova USA, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
100 Cyberonics Blvd., Houston, TX, 77058

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records